Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded at Zacks Research

Key Points

• Supernus Pharmaceuticals has been upgraded by Zacks Research from a "strong sell" to a "hold" rating, indicating a shift in analysts' outlook on the stock.
• The company's stocks were also rated "buy" by Wall Street Zen, and Supernus currently has an average rating of "Moderate Buy" with a consensus target price of $41.00.
• Insider trading activity includes CEO Jack A. Khattar selling 140,000 shares, reducing his ownership by nearly 12%, while several large investors have recently increased their stakes in the company.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) was upgraded by Zacks Research from a "strong sell" rating to a "hold" rating in a research report issued on Tuesday, August 19th,Zacks.com reports.

Several other brokerages also recently commented on SUPN. Cantor Fitzgerald boosted their target price on Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an "overweight" rating in a report on Wednesday, August 6th. Wall Street Zen raised Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Two investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $41.00.

Supernus Pharmaceuticals Price Performance

Shares of SUPN traded up $0.03 on Tuesday, hitting $44.46. The company's stock had a trading volume of 105,529 shares, compared to its average volume of 639,400. The company has a market capitalization of $2.49 billion, a PE ratio of 38.66 and a beta of 0.74. Supernus Pharmaceuticals has a fifty-two week low of $29.16 and a fifty-two week high of $45.60. The company has a 50 day moving average price of $35.64 and a 200 day moving average price of $33.69.

Insider Activity

In other news, Director Frederick M. Hudson sold 7,457 shares of the stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $42.26, for a total value of $315,132.82. Following the transaction, the director owned 46,307 shares of the company's stock, valued at $1,956,933.82. This represents a 13.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Bethany Sensenig sold 5,369 shares of the stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $42.25, for a total value of $226,840.25. The disclosure for this sale can be found here. Insiders have sold a total of 152,826 shares of company stock valued at $6,424,773 in the last 90 days. 8.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in SUPN. Raiffeisen Bank International AG acquired a new position in shares of Supernus Pharmaceuticals in the 4th quarter valued at $25,000. Financial Management Professionals Inc. bought a new stake in shares of Supernus Pharmaceuticals in the 1st quarter valued at $30,000. Versant Capital Management Inc increased its position in shares of Supernus Pharmaceuticals by 6,931.3% in the 1st quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company's stock valued at $37,000 after buying an additional 1,109 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of Supernus Pharmaceuticals in the 1st quarter valued at $41,000. Finally, GF Fund Management CO. LTD. bought a new stake in shares of Supernus Pharmaceuticals in the 4th quarter valued at $42,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.